Silicone deposits in repackaged anti-VEGF may cause permanent IOP spikes

Kahook, Malik Y.
February 2011
Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p15
Academic Journal
The article focuses on the occurrence of intraocular pressure (IOP) spikes of patients that receive intravitreal injections, wherein it is said that IOP spikes is due to the silicone oil deposits that leach from the repackage vials of anti-vascular endothelial growth factor (VEGF) agents.


Related Articles

  • Ranibizumab: points to consider when using it to treat neovascular age-related macular degeneration according to EU labelling. Lyseng-Williamson, Katherine; Frampton, James // Drugs & Therapy Perspectives;Sep2013, Vol. 29 Issue 9, p268 

    Ranibizumab (Lucentis), an inhibitor of multiple vascular endothelial growth factor A isoforms, is approved for the intravitreal treatment of neovascular (wet) age-related macular degeneration (AMD). In clinical trials in patients with neovascular AMD, monthly or less frequent injections of...

  • Judicious use of anti-VEGF agents advised as 'reasonable'. Reichel, Elias // Ocular Surgery News;3/10/2011, Vol. 29 Issue 5, p18 

    The article reports on the reasonable advice on the judicious use of anti-vascular endothelial growth factors (VEGF) agents for age-related macular degeneration (AMD) treatment.

  • Comparison studies of anti-VEGF agents a 'global effort'. Boyle, Erin L.; Harcharek, Alexandra; Hasson, Matt; Hsvidas, Cara; Nale, Patricia; Master, Joseph; Pagnani, Michelle; Preston, Courtney // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p25 

    The article reports on the presentation by doctor Daniel F. Martin on the comparison studies and international effort to understand the differences between the two anti-vascular endothelial growth factor (VEGF) agents, ranibizumab and bevacizumab.

  • Repeated anti-VEGF injections may alter RNFL thickness. Biro, Ashley // Ocular Surgery News;2/10/2013, Vol. 31 Issue 3, p21 

    The article discusses that anti vascular endothelial growth factor (anti-VEGF) injections can alter retinal nerve fiber layer (RNFL) thickness.

  • Anti-VEGF Dials Up the Pressure. Shechtman, Diana L.; Karpecki, Paul M. // Review of Optometry;9/15/2012, Vol. 149 Issue 9, p97 

    The article discusses the problems related to increment in the intraocular pressure (IOP) after the anti-vascular endothelial growth factor (VEGF) therapy. It mentions that intravitreal injection of Avastin and Lucentis is used for the treatment of several retinal abnormalities including retinal...

  • Anti-VEGF injections may not be preferred for AMD patients with poor baseline visual acuity. Pagnani, Michelle // Ocular Surgery News;3/25/2012, Vol. 30 Issue 6, p10 

    The article reports on a study which found that for those with age-related macular degeneration and poor baseline acuity, consideration of an alternative to anti-vascular epithelial growth factor (VEGF) therapy may be warranted.

  • Novel therapy targets integrin receptors. Karageozian, Vicken // Ophthalmology Times;Oct2015, Vol. 40 Issue 17, p42 

    The article discusses the result of the clinical trial of ALG-1001 from Allegro Ophthalmics for the treatment of vitreoretinal disease. Topics covered include the comparability of ALG-1001 to that of anti-vascular endothelial growth factor agents, the reasons for targeting integrins in...

  • VMA does not affect visual acuity after anti-VEGF injections for polypoidal choroidal vasculopathy. Kronemyer, Bob // Ocular Surgery News;2/25/2014, Vol. 32 Issue 4, p26 

    The article reports that posterior vitreomacular adhesion (VMA) was not associated with visual outcomes after intravitreal anti-vascular endothelial growth factor (VEGF) therapy for polypoidal choroidal vasculopath based on a study led by ophthalmologist Dr. Han Joo Cho. Topics discussed include...

  • Combining anti-PDGF with anti-VEGF may improve visual acuity, reduce AMD treatment burden.  // Ocular Surgery News;7/25/2012, Vol. 30 Issue 14, Special section p1 

    The article states that the complex disease process 'Advanced age-related macular degeneration be treated by modulating two factors 'VEGF' and 'PDGF'.When anti VEGF therapy is combined with anti platelet derived growth factor aptamer it leads to a better visual outcome.The limitation of anti...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics